Spread | 0.06 | ||||
Long position overnight fee Long position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
Overnight fee time | 21:00 (UTC) | ||||
Currency | USD | ||||
Min traded quantity | 1 | ||||
Margin | 20 | ||||
Stock exchange | United States of America | ||||
Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
Prev. Close | 0.65 |
Open | 0.68 |
1-Year Change | -79.2% |
Day's Range | 0.66 - 0.68 |
Phio Pharmaceuticals Corp. is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) INTASYL therapeutic platform. The Company has developed a product platform based on its INTASYL technology that allows selective non-genetically modified programming of adoptive cell therapy (ACT) cells and of the tumor micro-environment (TME), resulting in reduced immune inhibition and in improved immunotherapy. Its lead product candidate, PH-762, is an INTASYL compound that targets the checkpoint protein PD-1, which acts as a type of switch that prevents T cells from attacking certain cells, such as cancer cells, in the body. Its second product candidate, PH-894, is an INTASYL compound that targets BRD4, which is a regulator of gene expression impacting cell differentiation. It is also developing PH-804, which targets the suppressive immune receptor TIGIT.
BRIEF: For the nine months ended 30 September 2021, Phio Pharmaceuticals Corp revenues was not reported. Net loss increased 55% to $9.8M. Higher net loss reflects Research & Development Expenses - Balanc increase from $3.2M to $7M (expense), Labor & Related Expenses in SGA increase from $93K to $262K (expense), Stock-based Compensation in R&D increase from $17K to $80K (expense).
Common stock $.0001 Par, 1500M shares auth., 100,439,841 issd. Insider own 52.94%. 07/13, 1-for-30 reverse stock split. 04/16, 1-for-10 reverse stock split.